EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma

Maximilian J Mair, Sabrina Hartenbach, Erwin Tomasich, Sybren L N Maas, Sarah A Bosch, Georg Widhalm, Franziska Eckert, Felix Sahm, Johannes A Hainfellner, Markus Hartenbach, Anna S Berghoff, Matthias Preusser und 1 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07075-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Maximilian J Mair und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, LMU Hospital, Ludwig Maximilians University Munich, Munich, Germany. Hauptthemen laut MEDLINE: Meningioma, Receptors, Somatostatin, Serine Endopeptidases, Meningeal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Klinikum der Universität München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

High-grade meningiomas have high recurrence rates and limited prognosis. Radioligand therapies are approved in extracranial malignancies, but their value in brain tumours including meningiomas is unclear, as data on target expression is scarce.

Methods

CNS WHO grade 2 and 3 meningioma samples were immunohistochemically stained for somatostatin receptor 2a (SSTR2a), fibroblast activation protein (FAP), and human epidermal growth factor receptors 2/3 (HER2/HER3). Target expression was correlated with (epi-)genetic tumour subtyping by DNA methylation analysis, genetic alterations, and survival.

Results

Meningioma samples of 58 patients were included. SSTR2a expression (membranous/cytoplasmic) was observed in 43/55 (78.2%), and FAP expression in 15/58 (25.9%) evaluable samples, with HER2 and HER3 expression in one specimen each (1.7%). Membranous SSTR2a expression was strong in 18 (32.7%), intermediate in 12 (21.8%), and weak in 11 (20.0%) samples. While SSTR2a expression was more homogenous and mainly seen in regions with higher cellularity, FAP immunoreactivity was predominantly seen in tumour stroma and regions of lower cellularity. SSTR2a immunoreactivity was associated with TRAF7 wildtype status ( p = 0.034). FAP expression was more frequent in meningiomas of CNS WHO grade 3 (vs. CNS WHO 2; p < 0.001), and samples with NF2 mutations ( p = 0.032) or CDKN2A/B deletions ( p = 0.013) compared to wildtype. FAP and SSTR2a expression (present vs. absent) were not associated with overall survival ( p > 0.05).

Conclusion

SSTR2a and FAP are expressed in high-grade meningioma samples to a variable extent, and differences across meningioma subtypes underscore the need for biomarkers to improve patient selection. Spatial heterogeneity of target expression should be considered in radioligand therapy design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaReceptors, SomatostatinSerine EndopeptidasesMeningeal NeoplasmsErb-b2 Receptor Tyrosine KinasesMembrane ProteinsGelatinasesGene Expression Regulation, NeoplasticHumansFemaleMiddle AgedMaleAgedAdultNeoplasm GradingEndopeptidasesDNA MethylationAged, 80 and overReceptor, ErbB-3Fibroblast Activation Protein Alpha

Stichwörter der Autor:innen

Brain tumourFibroblast activating proteinMeningiomaSomatostatin receptorTheranostics

Substanzen

Receptors, SomatostatinSerine EndopeptidasesErb-b2 Receptor Tyrosine KinasesMembrane ProteinsGelatinasesEndopeptidasesReceptor, ErbB-3Fibroblast Activation Protein AlphaERBB2 protein, humanERBB3 protein, human

Autor:innen und Institutionen

  • Department of Nuclear Medicine, LMU Hospital, Ludwig Maximilians University Munich, Munich, Germany.
  • Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • MINUTEmedical GmbH, Vienna, Austria.
  • Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Nathalie L Albert

Förderung

  • Klinikum der Universität München

Zitieren

APA

Mair, M. J., Hartenbach, S., Tomasich, E., Maas, S. L. N., Bosch, S. A., Widhalm, G., Eckert, F., Sahm, F., Hainfellner, J. A., Hartenbach, M., Berghoff, A. S., Preusser, M., & Albert, N. L. (2025). Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07075-8

Vancouver

Mair MJ, Hartenbach S, Tomasich E, Maas SLN, Bosch SA, Widhalm G, et al. Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07075-8

BibTeX
@article{Mair2025,
  author = {Mair, Maximilian J and Hartenbach, Sabrina and Tomasich, Erwin and Maas, Sybren L N and Bosch, Sarah A and Widhalm, Georg and Eckert, Franziska and Sahm, Felix and Hainfellner, Johannes A and Hartenbach, Markus and Berghoff, Anna S and Preusser, Matthias and Albert, Nathalie L},
  title = {Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07075-8}
}
Kostenlos starten →